The Effects of Iontophoresis in Women With Gynoid Hidrolipodystrophy.
Primary Purpose
Caffeine, Cellulitis
Status
Completed
Phase
Phase 2
Locations
Brazil
Study Type
Interventional
Intervention
iontophoresis + caffeine
Sponsored by
About this trial
This is an interventional treatment trial for Caffeine
Eligibility Criteria
Inclusion Criteria:
- Patients with mild to moderate cellulite diagnosis will be included, according to the validated Photonumeric scale of cellulite severity
- Body mass index less than 30 (kg / m2)
Exclusion Criteria:
- Individuals who have a deregulated menstrual cycle who are pregnant;
- Breastfeeding or using some hormone;
- Antibiotic medication including steroids over 1 month of treatment of skin diseases; •Sensitivity or hypersensitivity of the skin;
- Use of the same or similar cosmetics or remedies on the glutes within 1 month;
- Surgical procedure (liposuction and skin treatments) in the region to be treated or planning some procedure within the study period;
- Chronic debilitating diseases such as asthma, diabetes or hypertension;
- Atopic dermatitis
Sites / Locations
- Rodrigo Antonio Carvalho Andraus
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Active Comparator
Active Comparator
Active Comparator
Arm Label
group 1
group 2
Group 3
Arm Description
topical gel base + caffeine.
iontophoresis + caffeine
iontophoresis
Outcomes
Primary Outcome Measures
thickness
change from baseline subcutaneous adipose tissue thickness at after 10 sessions
Secondary Outcome Measures
temperature
change from baseline superficial temperature of the gluteous skin at after 10 sessions
score quality of life
change from baseline quality of life impact in patients with cellulits at after 10 sessions
Full Information
NCT ID
NCT03556917
First Posted
May 15, 2018
Last Updated
April 15, 2019
Sponsor
Universidade Norte do Paraná
1. Study Identification
Unique Protocol Identification Number
NCT03556917
Brief Title
The Effects of Iontophoresis in Women With Gynoid Hidrolipodystrophy.
Official Title
The Effects of Iontophoresis in Women With Gynoid Hidrolipodystrophy.
Study Type
Interventional
2. Study Status
Record Verification Date
April 2019
Overall Recruitment Status
Completed
Study Start Date
June 14, 2018 (Actual)
Primary Completion Date
March 17, 2019 (Actual)
Study Completion Date
April 4, 2019 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Universidade Norte do Paraná
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Introduction: Gynoid hydrolipodystrophy (HLDG) or cellulitis is a subcutaneous tissue disorder, with several strategies for its treatment, such as caffeine and iontophoresis. Objective: To evaluate the effects of caffeine-associated iontophoresis for the treatment of HLDG. Methods: In a longitudinal study, participants will be evaluated for: photographic documentation, ultrasound imaging, thermography and quality of life questionnaire. If included, they will be separated into 3 randomized groups (n = 30). G1: use of base gel (n = 10); G2: use of iontophoresis and gel with caffeine (n = 10) and G3: use of iontophoresis alone (n = 10). The groups will be treated with 10 sessions, 2 times per week. After that they will be reevaluated. Statistical analysis: The software used will be the SPSS StatisticalPackage (IBM SPSS Statistics, Chicago, IL, USA). The data distribution will be analyzed by the Shapiro-Wilk test. In case of normal distribution, the data will be described as mean ± standard deviation; otherwise, as median [interquartile range 25-75%]. For comparison of the data, we will use ANOVA and for comparison of means the Tukey test and case not normal distribution, krulskal-Wallis test and the Dunns test. The level of statistical significance adopted will be P <0.05. Expected contributions: It is expected that investigators can contribute to the treatment of patients with HLDG and analyze the effects of iontophoresis with caffeine, both in clinical and scientific practice, providing a method that is valid and reliable for this purpose; multidisciplinary training of highly qualified human resources and the strengthening and consolidation of a research team.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Caffeine, Cellulitis
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2, Phase 3
Interventional Study Model
Factorial Assignment
Model Description
It is a longitudinal and randomized
Masking
None (Open Label)
Allocation
Randomized
Enrollment
30 (Actual)
8. Arms, Groups, and Interventions
Arm Title
group 1
Arm Type
Active Comparator
Arm Description
topical gel base + caffeine.
Arm Title
group 2
Arm Type
Active Comparator
Arm Description
iontophoresis + caffeine
Arm Title
Group 3
Arm Type
Active Comparator
Arm Description
iontophoresis
Intervention Type
Combination Product
Intervention Name(s)
iontophoresis + caffeine
Intervention Description
we will use cafeislaine c (caffeine) +galvanic current
Primary Outcome Measure Information:
Title
thickness
Description
change from baseline subcutaneous adipose tissue thickness at after 10 sessions
Time Frame
through study completion, an average of 1 year.
Secondary Outcome Measure Information:
Title
temperature
Description
change from baseline superficial temperature of the gluteous skin at after 10 sessions
Time Frame
through study completion, an average of 1 year.
Title
score quality of life
Description
change from baseline quality of life impact in patients with cellulits at after 10 sessions
Time Frame
through study completion, an average of 1 year.
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
40 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Patients with mild to moderate cellulite diagnosis will be included, according to the validated Photonumeric scale of cellulite severity
Body mass index less than 30 (kg / m2)
Exclusion Criteria:
Individuals who have a deregulated menstrual cycle who are pregnant;
Breastfeeding or using some hormone;
Antibiotic medication including steroids over 1 month of treatment of skin diseases; •Sensitivity or hypersensitivity of the skin;
Use of the same or similar cosmetics or remedies on the glutes within 1 month;
Surgical procedure (liposuction and skin treatments) in the region to be treated or planning some procedure within the study period;
Chronic debilitating diseases such as asthma, diabetes or hypertension;
Atopic dermatitis
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Rodrigo A Andraus
Organizational Affiliation
Universidade Norte do Paraná
Official's Role
Principal Investigator
Facility Information:
Facility Name
Rodrigo Antonio Carvalho Andraus
City
Londrina
State/Province
Paraná
ZIP/Postal Code
86.041-140
Country
Brazil
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
19220646
Citation
Hexsel DM, Dal'forno T, Hexsel CL. A validated photonumeric cellulite severity scale. J Eur Acad Dermatol Venereol. 2009 May;23(5):523-8. doi: 10.1111/j.1468-3083.2009.03101.x. Epub 2009 Feb 13.
Results Reference
result
PubMed Identifier
24010809
Citation
Yoo MA, Seo YK, Ryu JH, Back JH, Koh JS. A validation study to find highly correlated parameters with visual assessment for clinical evaluation of cosmetic anti-cellulite products. Skin Res Technol. 2014 May;20(2):200-7. doi: 10.1111/srt.12106. Epub 2013 Sep 7.
Results Reference
result
Learn more about this trial
The Effects of Iontophoresis in Women With Gynoid Hidrolipodystrophy.
We'll reach out to this number within 24 hrs